Metagenomi Closes Oversubscribed Series B Financing Totaling $275M To Advance Lead Therapeutic Programs Into Clinical Development And Grow Genetic Medicines Pipeline
Round Type
Series B
EmeryvilleInformation TechnologyBiotechnologyInvestors
Description
Metagenomi, a genetic medicines company with a versatile portfolio of wholly owned, next-generation gene editing systems, today announced the close of a Series B extension financing, co-led by Novo Holdings A/S, Catalio Capital Management and SymBiosis, with participation from new and existing investors. This $100M financing brings the total Series B proceeds to $275M, with over 30 investment groups participating. In connection with the financing, Ray Camahort, Ph.D., Partner at Novo Ventures, will join Metagenomi’s board as an observer.
Quick answer
Metagenomi Therapeutics, Inc. raised an undisclosed amount in a Series B round, dated January 5, 2023. Investors: Ray Camahort, Ph.D., Partner At Novo Ventures, Catalio Capital Management and Novo Holdings A/S. Metagenomi Therapeutics, Inc. is based in Emeryville, California, United States.
- How much did Metagenomi Therapeutics, Inc. raise?
- Metagenomi Therapeutics, Inc. raised an undisclosed amount in a Series B round on January 5, 2023.
- Who invested in Metagenomi Therapeutics, Inc?
- Ray Camahort, Ph.D., Partner At Novo Ventures, Catalio Capital Management and Novo Holdings A/S are named as investors in this round.
- What does Metagenomi Therapeutics, Inc. do?
- Gene editing is changing the world.
- Where is Metagenomi Therapeutics, Inc. based and how big is it?
- Metagenomi Therapeutics, Inc. is based in Emeryville, California, United States.
- Who are the decision-makers at Metagenomi Therapeutics, Inc?
- Fundz holds 1 contact at Metagenomi Therapeutics, Inc., including the President & COO. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology around the same time
Companies in the same sectors as Metagenomi Therapeutics, Inc. that raised within 45 days of this round, from Fundz verified event records.
- NovAb raised $300K (Seed) on February 17, 2023.
- Evofem Biosciences raised $1.4M (Seed) on February 17, 2023.
- Pathos AI raised $20M on February 17, 2023.
- CardioMech AS raised $4.5M (Seed) on February 16, 2023.
- Previa Medical raised $2.2M (Seed) on February 16, 2023.
- 1606 Corp raised $20M (Funding Round) on February 16, 2023.
Who to call at Metagenomi Therapeutics, Inc., and when
A new round usually means Metagenomi Therapeutics, Inc. is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Metagenomi Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Metagenomi Therapeutics, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Metagenomi Therapeutics, Inc.. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Metagenomi Therapeutics, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansMetagenomi Therapeutics, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.